Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemiaDavide Rossi, Marco Ladetto, Michela Boi et al.|Leukemia|2009Cited by 98
High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomibManuela Gambella, Antonio Palumbo, Alberto Rocci et al.|Haematologica|2014Cited by 56
Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysisStefania Oliva, Paola Omedè, Manuela Gambella et al.|Oncotarget|2016Cited by 36
Telomere loss in Philadelphia-negative hematopoiesis after successful treatment of chronic myeloid leukemia: Evidence for premature aging of the myeloid compartmentChiara Lobetti‐Bodoni, Marco Ladetto, Dario Ferrero et al.|Mechanisms of Ageing and Development|2012Cited by 9
LONG-TERM RESULTS of the GIMEMA VTD Consolidation TRIAL In Autografted MULTIPLE Myeloma PATIENTS (VEL-03-096): IMPACT of Minimal RESIDUAL DISEASE Detection by REAL Time Quantitative PCR On LATE Recurrences and Overall SURVIVALMarco Ladetto, Antonio Palumbo, Simone Ferrero et al.|Blood|2011Cited by 9